Titan Biotech

Which are the latest news on Titan Biotech?

Why is Titan Biotech Ltd falling/rising?

As of 12-Jun, Titan Biotech Ltd's stock price is rising with a 2.35 point increase, totaling a 3.43% gain over the last three days. Despite this, it has underperformed its sector today and shows mixed signals regarding investor engagement.

As of 12-Jun, Titan Biotech Ltd's stock price is currently rising, as indicated by a change of 2.35, or 0.53%, in the positive direction. The stock has been gaining for the last three days, with a total increase of 3.43% during this period. Additionally, the stock reached an intraday high of Rs 458, reflecting a rise of 3.53%. <BR><BR>However, it is important to note that despite these positive movements, the stock has underperformed its sector by 0.35% today. The stock's performance over the past week shows a modest increase of 0.55%, but it has experienced a decline of 2.79% over the past month. Year-to-date, the stock has shown a remarkable increase of 111.02%, and over the past year, it has surged by 417.15%. <BR><BR>The stock's current price is above its 5-day, 20-day, 100-day, and 200-day moving averages, although it is below the 50-day moving average. This indicates a generally positive trend, but the falling investor participation, with a delivery volume decrease of 29.97% compared to the 5-day average, suggests a potential concern regarding sustained interest in the stock. Overall, while Titan Biotech Ltd is currently experiencing a rise in its stock price, there are mixed signals regarding its performance and investor engagement.

How big is Titan Biotech?

As of 10th June, Titan Biotech Ltd has a market capitalization of 1,785.00 Cr, with recent net sales of 206.19 Cr and a net profit of 29.88 Cr. Shareholder's funds are 153.40 Cr, and total assets amount to 174.71 Cr as of March 2025.

As of 10th June, Titan Biotech Ltd has a market capitalization of 1,785.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, Titan Biotech reported Net Sales of 206.19 Cr and a Net Profit of 29.88 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 153.40 Cr and Total Assets of 174.71 Cr.

Who are in the management team of Titan Biotech?

The management team of Titan Biotech includes Naresh Kumar Singla and Suresh Chand Singla as Managing Directors, along with other key members such as Charanjit Singh (Company Secretary), and several Non-Executive and Independent Directors.

The management team of Titan Biotech includes the following individuals:<BR><BR>1. **Naresh Kumar Singla** - Managing Director<BR>2. **Suresh Chand Singla** - Managing Director<BR>3. **Manju Singla** - Non-Executive & Non-Independent Director<BR>4. **Charanjit Singh** - Company Secretary & Compliance Officer<BR>5. **Supriya Singla** - Non-Executive & Non-Independent Director<BR>6. **Rekha Dalmia** - Non-Executive & Independent Director<BR>7. **Rohit Jain** - Independent Director<BR>8. **Abhishek Agarwal** - Independent Director<BR>9. **Raja Singla** - Whole-time Director<BR><BR>If you need more information about any specific member or their roles, feel free to ask!

Who are the peers of the Titan Biotech?

Titan Biotech's peers include Jubilant Agri, NOCIL, DDev Plastiks, Camlin Fine, Bhansali Engg., S H Kelkar & Co., Vidhi Specialty, Indokem, and Nitta Gelatin. Titan Biotech has the highest 1-year return at 412.73%, while Camlin Fine has the lowest at -57.53%.

Peers: Titan Biotech's peers include Jubilant Agri, NOCIL, DDev Plastiks, Camlin Fine, Bhansali Engg., S H Kelkar & Co., Vidhi Specialty, Indokem, and Nitta Gelatin.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jubilant Agri, DDev Plastiks, NOCIL, Bhansali Engg., Nitta Gelatin, and Titan Biotech, while Average management risk is found at S H Kelkar & Co., Vidhi Specialty, and Indokem. Growth is rated as Excellent for Jubilant Agri, Good for DDev Plastiks, and Average for Nitta Gelatin, while Below Average growth is noted for Camlin Fine, Bhansali Engg., Titan Biotech, S H Kelkar & Co., and Vidhi Specialty, and the rest. Capital Structure is rated Excellent for Jubilant Agri, DDev Plastiks, NOCIL, Bhansali Engg., Titan Biotech, and Nitta Gelatin, while Average is noted for S H Kelkar & Co., and Below Average for Camlin Fine and Indokem.<BR><BR>Return Snapshot: Titan Biotech has the highest 1-year return at 412.73%, while Camlin Fine has the lowest at -57.53%. Compared to its peers, Titan Biotech's return is significantly higher. Additionally, S H Kelkar & Co., Vidhi Specialty, and Camlin Fine have negative six-month returns.

What does Titan Biotech do?

Titan Biotech Ltd. is a New Delhi-based company specializing in the manufacture of Biological Peptones, Extracts, and Dehydrated Culture media within the Specialty Chemicals industry. As of March 2026, it reported net sales of 49 Cr and a net profit of 7 Cr, with a market cap of INR 1,785 Cr.

Overview:<BR>Titan Biotech Ltd. is a New Delhi-based company engaged in the manufacture of Biological Peptones, Extracts, and Dehydrated Culture media, operating within the Specialty Chemicals industry and classified as a Micro Cap.<BR><BR>History:<BR>Titan Biotech Ltd. was incorporated in an unspecified year, and the latest financial results reported are for the quarter ending March 2026, showcasing a net sales and profit performance.<BR><BR>Financial Snapshot:<BR>- Net Sales: 49 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 7 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 1,785 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 61.00<BR>- Industry P/E: 42<BR>- Dividend Yield: 0.09%<BR>- Debt Equity: 0.02<BR>- Return on Equity: 16.46%<BR>- Price to Book: 9.88<BR><BR>Contact Details:<BR>- Address: A-902 A RIICO Industrial Area, Phase III Alwar District Bhiwadi Rajasthan : 301019<BR>- Tel: 91-011-27355742/27674615<BR>- Email: cs@titanbiotechltd.com/hrd@titanbio<BR>- Website: http://www.titanbiotechltd.com

Should I buy, sell or hold Titan Biotech Ltd?

Are Titan Biotech Ltd latest results good or bad?

Titan Biotech Ltd's latest Q4 FY26 results show strong year-on-year growth, with a 66.17% increase in net profit and a 38.84% rise in net sales. However, there are concerns due to sequential declines in both metrics, suggesting investors should watch for future performance trends.

Titan Biotech Ltd's latest results for Q4 FY26 present a mixed picture. On one hand, the company reported a consolidated net profit of ₹6.73 crore, which is a significant increase of 66.17% year-on-year. This indicates strong growth compared to the same quarter last year. Additionally, net sales reached ₹48.83 crore, reflecting a 38.84% year-on-year increase, showcasing robust top-line growth.<BR><BR>However, there are some concerns regarding sequential performance. Both net profit and net sales declined compared to the previous quarter, with net profit down 21.10% and net sales down 13.59%. This sequential decline may raise questions about the sustainability of growth, especially in light of typical seasonality patterns in the specialty chemicals sector.<BR><BR>The operating margin also showed improvement, reaching 19.89%, which is a notable increase from the previous year. This suggests that the company is managing its costs effectively and benefiting from operational leverage.<BR><BR>Overall, while the year-on-year growth metrics are impressive, the sequential declines warrant caution. Investors should monitor future performance to determine if this is a temporary fluctuation or indicative of a broader trend.

When is the next results date for Titan Biotech Ltd?

The next results date for Titan Biotech Ltd is 30 May 2026.

The next results date for Titan Biotech Ltd is scheduled for 30 May 2026.

Is Titan Biotech technically bullish or bearish?

As of November 18, 2025, Titan Biotech's technical trend is mildly bullish, supported by bullish MACD and Bollinger Bands, despite mixed signals from KST and a mildly bearish Dow Theory.

As of 18 November 2025, the technical trend for Titan Biotech has changed from bullish to mildly bullish. The weekly MACD remains bullish, supporting a positive outlook, while the monthly MACD is also bullish, indicating strength over a longer time frame. The Bollinger Bands are showing a mildly bullish stance on both weekly and monthly charts, which aligns with the daily moving averages that are also mildly bullish. However, the KST indicates a mixed signal with a bullish weekly reading but a mildly bearish monthly reading. The Dow Theory shows a mildly bearish stance on the weekly chart, suggesting some caution. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and Bollinger Bands, despite some mixed signals from KST and Dow Theory.

How has been the historical performance of Titan Biotech?

Titan Biotech's historical performance shows fluctuating financial metrics, with net sales and profits declining from Mar'24 to Mar'25, despite an increase in total assets. Operating profit decreased significantly, indicating challenges in profitability.

Answer:<BR>The historical performance of Titan Biotech shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Titan Biotech's net sales have shown variability, with a peak of 164.07 Cr in Mar'24, followed by a decline to 156.45 Cr in Mar'25. Total operating income mirrored this trend, reaching 164.07 Cr in Mar'24 before decreasing to 156.45 Cr in Mar'25. The company's total expenditure, excluding depreciation, increased from 129.79 Cr in Mar'24 to 131.02 Cr in Mar'25. Operating profit (PBDIT) also saw a decline from 34.28 Cr in Mar'24 to 25.43 Cr in Mar'25, reflecting a decrease in operating profit margin from 20.89% to 16.25%. Profit before tax decreased from 31.53 Cr in Mar'24 to 24.37 Cr in Mar'25, leading to a profit after tax of 18.27 Cr in Mar'25, down from 23.66 Cr in Mar'24. The consolidated net profit followed suit, decreasing from 24.85 Cr in Mar'24 to 21.53 Cr in Mar'25. On the balance sheet, total assets rose from 157.03 Cr in Mar'24 to 174.71 Cr in Mar'25, while total liabilities also increased from 157.03 Cr to 174.71 Cr. The company maintained a stable equity capital of 8.26 Cr over the years. Cash flow from operating activities remained relatively stable, with a slight decrease from 21.00 Cr in Mar'24 to 20.00 Cr in Mar'25, while net cash inflow improved from a negative 2.00 Cr in Mar'24 to a positive 2.00 Cr in Mar'25. Overall, Titan Biotech's financial performance reflects challenges in profitability despite growth in total assets.

Is Titan Biotech overvalued or undervalued?

As of August 18, 2025, Titan Biotech is considered very expensive and overvalued, with a PE ratio of 17.32, an EV to EBITDA of 14.59, and a Price to Book Value of 2.48, especially when compared to peers like Solar Industries and Godrej Industries, despite a recent stock performance uptick.

As of 18 August 2025, Titan Biotech's valuation grade has moved from expensive to very expensive, indicating a significant deterioration in its valuation outlook. The company is currently deemed overvalued. Key ratios include a PE ratio of 17.32, an EV to EBITDA of 14.59, and a Price to Book Value of 2.48, which suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison with peers, Titan Biotech's PE ratio is notably lower than that of Solar Industries, which stands at 108.25, and Godrej Industries, which has a PE ratio of 42.48, reinforcing the perception of Titan's overvaluation. Furthermore, despite a recent uptick in stock performance with a 4.18% return over the past week compared to a modest 0.83% for the Sensex, the year-to-date return of -37.09% highlights ongoing challenges. Overall, Titan Biotech's current valuation metrics and peer comparisons suggest that it is overvalued in the specialty chemicals sector.

Who are the top shareholders of the Titan Biotech?

The top shareholders of Titan Biotech include Titan Securities Ltd with 33.59%, while individual investors hold 29.2%. The highest public shareholder is Ankit Goyal, owning 1.57%, and there are no pledged promoter holdings or investments from mutual funds or foreign institutional investors.

The top shareholders of Titan Biotech primarily consist of its promoters, with Titan Securities Ltd holding the largest share at 33.59%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Ankit Goyal, who owns 1.57%. Additionally, individual investors collectively hold 29.2% of the company's shares.

Has Titan Biotech declared dividend?

Titan Biotech Ltd has declared a 20% dividend, amounting to 2 per share, with an ex-date of September 23, 2024. Recent total returns show significant fluctuations, with a -51.52% return over the last 6 months, but positive growth over longer periods, including a 519.38% return over the past 5 years.

Titan Biotech Ltd has declared a 20% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 2 per share<BR>- Ex-date: 23 Sep 24<BR><BR>Dividend Yield: 0.48%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -51.52%, with a dividend return of 0%, resulting in a total return of -51.52%.<BR><BR>Over the past year, the price return was -20.31%, the dividend return was 0.38%, leading to a total return of -19.93%.<BR><BR>In the 2-year period, the price return was 56.16%, the dividend return was 1.46%, resulting in a total return of 57.62%.<BR><BR>For the 3-year period, the price return was 85.88%, with a dividend return of 2.49%, culminating in a total return of 88.37%.<BR><BR>In the last 4 years, the price return was 38.8%, the dividend return was 1.72%, resulting in a total return of 40.52%.<BR><BR>Over the past 5 years, the price return was 509.14%, with a dividend return of 10.24%, leading to a total return of 519.38%.<BR><BR>Overall, Titan Biotech has declared a dividend, but the recent total returns indicate significant fluctuations, particularly in the short term, with negative returns over the last 6 months and 1 year, while longer-term returns show substantial growth.